Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

12.74
+0.07500.59%
Volume:173.24K
Turnover:2.20M
Market Cap:1.13B
PE:-3.78
High:12.76
Open:12.71
Low:12.69
Close:12.66
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:5.64
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:23.34
PE(LYR):-4.01

Loading ...

Feb 27, 2025

Major Issues Report

Form 8-K - Current report
Feb 05, 2025

Major Issues Report

Form 8-K - Current report
Jan 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 28, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 28, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 28, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 28, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 28, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 15, 2025

Major Issues Report

Form 8-K - Current report
Jan 07, 2025

Major Issues Report

Form 8-K - Current report
Dec 20, 2024

Major Issues Report

Form 8-K - Current report
Dec 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 20, 2024

Major Issues Report

Form 8-K - Current report
Nov 18, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 07, 2024

Major Issues Report

Form 8-K - Current report
Nov 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 17, 2024

Major Issues Report

Form 8-K - Current report
Aug 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]